rs386833565
Positions:
Variant summary
Our verdict is Uncertain significance. Variant got 1 ACMG points: 3P and 2B. PM2PP5BP4BP7
The NM_000170.3(GLDC):c.2607C>A(p.Pro869=) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000669 in 1,613,308 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.000085 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000065 ( 0 hom. )
Consequence
GLDC
NM_000170.3 synonymous
NM_000170.3 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: -0.436
Genes affected
GLDC (HGNC:4313): (glycine decarboxylase) Degradation of glycine is brought about by the glycine cleavage system, which is composed of four mitochondrial protein components: P protein (a pyridoxal phosphate-dependent glycine decarboxylase), H protein (a lipoic acid-containing protein), T protein (a tetrahydrofolate-requiring enzyme), and L protein (a lipoamide dehydrogenase). The protein encoded by this gene is the P protein, which binds to glycine and enables the methylamine group from glycine to be transferred to the T protein. Defects in this gene are a cause of nonketotic hyperglycinemia (NKH).[provided by RefSeq, Jan 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 1 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 9-6540109-G-T is Pathogenic according to our data. Variant chr9-6540109-G-T is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 56084.We mark this variant Likely_pathogenic, oryginal submissions are: {Likely_pathogenic=2, Uncertain_significance=1, Pathogenic=2}. Variant chr9-6540109-G-T is described in Lovd as [Pathogenic].
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.49). . Strength limited to SUPPORTING due to the PP5.
BP7
Synonymous conserved (PhyloP=-0.436 with no splicing effect.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GLDC | NM_000170.3 | c.2607C>A | p.Pro869= | synonymous_variant | 22/25 | ENST00000321612.8 | NP_000161.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GLDC | ENST00000321612.8 | c.2607C>A | p.Pro869= | synonymous_variant | 22/25 | 1 | NM_000170.3 | ENSP00000370737 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000854 AC: 13AN: 152144Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
13
AN:
152144
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000835 AC: 21AN: 251436Hom.: 0 AF XY: 0.000103 AC XY: 14AN XY: 135886
GnomAD3 exomes
AF:
AC:
21
AN:
251436
Hom.:
AF XY:
AC XY:
14
AN XY:
135886
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000650 AC: 95AN: 1461046Hom.: 0 Cov.: 29 AF XY: 0.0000647 AC XY: 47AN XY: 726946
GnomAD4 exome
AF:
AC:
95
AN:
1461046
Hom.:
Cov.:
29
AF XY:
AC XY:
47
AN XY:
726946
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000854 AC: 13AN: 152262Hom.: 0 Cov.: 32 AF XY: 0.0000940 AC XY: 7AN XY: 74442
GnomAD4 genome
AF:
AC:
13
AN:
152262
Hom.:
Cov.:
32
AF XY:
AC XY:
7
AN XY:
74442
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
4
AN:
3478
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:7Uncertain:1
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Non-ketotic hyperglycinemia Pathogenic:4Uncertain:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Apr 10, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | This sequence change affects codon 869 of the GLDC mRNA. It is a 'silent' change, meaning that it does not change the encoded amino acid sequence of the GLDC protein. This variant is present in population databases (rs386833565, gnomAD 0.01%). This variant has been observed in individual(s) with glycine encephalopathy (PMID: 15851735). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 56084). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant is not likely to affect RNA splicing. For these reasons, this variant has been classified as Pathogenic. - |
Likely pathogenic, no assertion criteria provided | literature only | Juha Muilu Group; Institute for Molecular Medicine Finland (FIMM) | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Oct 01, 2021 | NM_000170.2(GLDC):c.2607C>A(P869=) is a silent variant classified as a variant of uncertain significance in the context of GLDC-related glycine encephalopathy. P869= has been observed in cases with relevant disease (PMID: 15851735). Functional assessments of this variant are available in the literature (PMID: 15851735). P869= has been observed in population frequency databases (gnomAD: OTH 0.05%). In summary, there is insufficient evidence to classify NM_000170.2(GLDC):c.2607C>A(P869=) as pathogenic or benign. Please note: this variant was assessed in the context of healthy population screening. - |
Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | Jun 11, 2020 | Based on the classification scheme VCGS_Germline_v1.1.1, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss-of-function is a known mechanism of disease for this gene. (N) 0106 - This gene is known to be associated with autosomal recessive disease. (N) 0209 - Synonymous variant proven to affect splicing/expression of the transcript with uncertain effect on protein structure (exon 22). RNA studies demonstrated aberrant splicing resulting in three abnormally spliced transcripts (PMID: 15851735). (P) 0252 - Variant is homozygous. (N) 0304 - Variant is present in gnomAD <0.01 for a recessive condition (22 heterozygotes, 0 homozygotes). (P) 0508 - In-silico predictions for abnormal splicing are conflicting. (N) 0705 - No comparable variants have previous evidence for pathogenicity. (N) 0803 - Low previous evidence of pathogenicity in unrelated individuals. This variant has previously been reported in one large family and in an additional unrelated but haplotypically identical patient (PMID: 15851735, ClinVar). (P) 0901 - Strong evidence for segregation with disease. 8 affected individuals from the large family reported were found to be homozygous the variant (PMID: 15851735). (P) 1007 - No published functional evidence has been identified for this variant. (N) 1205 - Variant is maternally inherited. (N) 1206 - Variant is paternally inherited. (N) Legend: (P) - Pathogenic, (N) - Neutral, (B) - Benign - |
Glycine encephalopathy 1 Pathogenic:2
Pathogenic, no assertion criteria provided | literature only | OMIM | Apr 26, 2005 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center | Sep 22, 2024 | - - |
GLDC-related disorder Pathogenic:1
Likely pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 09, 2024 | The GLDC c.2607C>A variant is not predicted to result in an amino acid change (p.=). This variant was reported in the homozygous state in multiple individuals within one family and in one unrelated individual affected with glycine encephalopathy (Flusser et al. 2005. PubMed ID: 15851735). This variant was reported within the same family in 9 affected members and in the heterozygous state in all their unaffected parents, supporting variant segregation with disease (Flusser et al. 2005. PubMed ID: 15851735). mRNA studies confirmed that this variant results in exon 22 and exon 22 to 23 skipping, confirming the mechanism of pathogenicity for this synonymous (silent) variant (Flusser et al. 2005. PubMed ID: 15851735). This variant is reported in 0.011% of alleles in individuals of Latino descent in gnomAD. This variant is interpreted as likely pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at